The medical management of attention-deficit/hyperactivity disorder: Spoilt for choice?

South African Psychiatry Review

Volumn 9, Issue 3, 2006, Pages 143-151

  Venter, A ^a,b  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b Department of Paediatrics and Child Health ^*  (South Africa)

Author keywords

Attention deficit; Hyperactivity; Stimulants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; PSYCHOSTIMULANT AGENT; RISPERIDONE; RITALIN IR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANGINA PECTORIS; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BLOOD PRESSURE; BLURRED VISION; BODY WEIGHT DISORDER; BULIMIA; CLINICAL TRIAL; COMORBIDITY; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; DYSKINESIA; DYSPHORIA; EMOTIONAL DISORDER; FIXED DRUG ERUPTION; FOOD DRUG INTERACTION; GILLES DE LA TOURETTE SYNDROME; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; MEDICAL CARE; MEDICAL DECISION MAKING; NAUSEA; NERVOUSNESS; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PATHOLOGICAL CRYING; PATIENT CARE; PATIENT EDUCATION; PSYCHOSOCIAL WITHDRAWAL; PULSE PRESSURE; REBOUND; RESTLESSNESS; REVIEW; SLEEP DISORDER; SOCIOPATHY; SOMNOLENCE; SOUTH AFRICA; STOMACH PAIN; TABLET; TARDIVE DYSKINESIA; THORAX PAIN; TIC; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33751348263     PISSN: 18117805     EISSN: None     Source Type: Journal    
DOI: 10.4314/ajpsy.v9i3.30215     Document Type: Review

References (79)

1. Barkley RA, Dulcan M, Prior M, et al. International consensus statement on ADRD - January 2002, Clinical Child and family Psychology Review 2002:June
2. Biederman J, Faraone S, Merger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996;53:437-446
3. Gittelman R, Mannuzza S, Schenker S, Bonagura N. Hyperactive boys almost grow up 1. Psychiatric status. Arch Gen Psychiatry 1985;42:937-947
4. Milberger S, Biederman J, Faraone SV, Jones J. Further evidence of an association between maternal smoking and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998;27:352-358
5. Thapar A, Holmes J, Poulton K, Harrington R. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry 1999;174:105-111
6. Faraone SV, Biederman J, Weiffenbach B, et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry 1999;156:768-770.
7. Castellanos FX. Toward a pathophysiology of attentionl/deficit/ hyperactivity disorder. Clinical Pediatrics 1997;July:381-388
8. Cullbert TP, Banez GA, Reiff MI. Children who have attentional disorders: Interventions. Pediatrics in Review 1994;15:5-14
9. Cyr M, Brown CS. Current drug therapy recommendations for the treatment of Attention Deficit Hyperactivity Disorder. Drugs 1998;56:215-223
10. Bradley C. Behavior of children receiving Benzedrine. Am J Psychiatry 1937;94:577-585
11. Biederman J. Attention-deficit/hyperactivity disorder: A life -span perspective. J Clin Psychiatry 1998;59(suppl 7):4-16
12. Swanson JW, McBurnett K, Christaian DL, Wigal T. Stimulant medication and treatment of children with ADHD. In Ollendick TH, Prinz RJ, eds. Advances in Clinical Child Psychology New York, NY: Plenum Press, 1995:265-322
13. McClellan JM, Werry JS. Evidence-based treatments in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psychiatry 2003;42:1388-1400
14. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086
15. Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr 1999;88:298-303
16. Wilens TE, Spencer TJ. The stimulants revisited Child and Adolescent Psychiatric Clinics of North America 2000;9:573-603
17. Swanson JM, Cantwell D, Lemer M, McBurnett, Hanna G. Effects of stimulant medication on learning in children with ADHD. Journal of Learning Disabilities 1991;24:219-230.
18. Greenhill LL, Halperin JW, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999;38:503-512
19. Solanto MV, Conners CK. A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity. Psychophysiology 1998;27:190-205
20. Pelham WE, Aronoff HR, Midlam JK et al. A comparison of Fitalin and Adderall: efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics 1999;103(4). URL: http://www.pediatrics.org/cgi/content/full/103/4/e43
21. Swanson J, Kinsbourne M, Roberts W, Zucker K. Time response analysis of the effect of stimulant medication on the learning of children referred for hyperactivity. Pediatrics 1978;61:21-29.
22. Challman TD, Lipsky JJ. Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 2000;75:711-721
23. Wender EH. Managinq stimulant medication for attention-deficit/ hyperactivity disorder. Pediatrics in Review 2001;22:183-189
24. Moll GH, Hause S, Ruther E, Rothenbereger A, Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharm 2001;11:15-24
25. Gillberg C, Melander H, von Knorrig A-L, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity syndrome. Arch Gen Psychiatry 1997;54:857-64
26. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD wrth methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:748-756
27. Swanson J, Gupta S, Guinta D, et al. Acute tolerance of methylphenidate treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999;66:295-305.
28. Musser CJ, Ahmann PA, Theye FW, et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. Dev Behav Pediatr 1998;19:187-192
29. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once a day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107(6). URL: http://www.pediatrics.org/cgi/content/full/10716/e105
30. Wigal T, Swanson JM, Regino R, et al. Stimulant medications for the treatment of ADHD: efficacy and limitations. Ment Retard Dev Disabil Res Rev 1999;5:215-224
31. Pelham WE Jr, Sturges J, Hoza J et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491-501.
32. Birmaher BB, Greenhill L, Cooper T, Fried J, Maminski B. Sustained release methyphenidate: Pharmacokinetic studies in ADDH males. J AM Acad Child Adolesc Psychiatry 1989;28:768-772
33. Pelham WE, Greenslade KE, Vodde-Hamilton MA, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder a comparison of standard methylphenidate sustained-release methyphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-237
34. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2003;60:204-211.
35. Wilens T, Pelham W, Stem M, et al. ADHD treatment with once-daily OROS methylphenidate: Interim 12 month results from long-term open-label study. J Am ACAD Child Adolesc Psychiatry 2003,42:424-433
36. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized controlled trial of OROS methylpherudate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:883-892
37. EKa J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. The New England Journal of Medicine 1999;340:780-788
38. Antochi R, Stavrakaki C, Emery PC. Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgrad Med 2003;79:139-146
39. Gross-Tsur V, Manmor O, Van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective. J Pediatr 1997;130:40-44
40. The Tourette's Syndrome Study Group. Treatment of ADHD in children with tics. Neurolog. 2002;58:527-536.
41. Barkley RA, McMurray WB, Edelbrock CS & Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192
42. Pringsheim T, Davenport WJ, Lang A. Tics. Cur Opin Neurol 2003;16:523-527
43. Brown RT, Wynne ME, Slimmer LW. Attention deficit disorder and the effect of methylphenidate on attention, behavioral and cardiovascular functioning. J Clin Psychiatry 1984;45:473-476
44. Volkow N, Wang G, Fowler F, et al. Dopamine transporter occupancies in the human brain induced by therapeutic effects of oral methylphenidate. Am J Psychiatry 1998;155:1325-1331
45. Wilens TE. Attention-deficit/hyperactivity disorder and the substance abuse disorders: the nature of the relationship, subtypes at risk and treatment issues. Psychiatr Clin N Am 2004;27:283-301.
46. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy for Attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-185
47. Biederman J, Wilens T, Mick E, Spencer T & Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorders reduces risk for substance abuse. Pediatrics 1999;104:. URL: http://www.pediatriccs.org/cgi/content/full/104/2/e20
48. Klein-Schwartz, W. Abuse and toxicity of methylphenidate. Current Opinion in Pediatrics 2002;14:219-223.
49. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S. Predictors of height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psyciatry 2000;39(4)
50. Joshi SV. ADHD, growth deficits, and relationship to psychostimulant use. Pediatrics in Review 2002;23:67-68
51. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: Evidence for disorder associated growth delays? J Am Acad Child Adolesc Psychiatry 1996;35:1460-1469
52. Spencer T, Biederman J, Wilens T, et al. Nonstimulant treatment of adult attention-deficit hyperactivity disorder. Psychiatric Clin N Am. 2004;27:373-383
53. Silver LB. Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatric Clinics of North America 1999;46:965-974
54. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432
55. Kratchovil CJ, Heiligensten JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children withy ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784
56. Michelson D, Faries D, Werrucke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose response study. Pediatrics 2001;108:1-9
57. Caballero J, Milap CN. Atomoxetine hydrochloride for the treatment of Attention-deficit/hyperactivity disorder. Clinical Therapeutics 2003;25:3065-3083
58. Elland LS, Guest AL. Atomoxitine treatment of Attention-deficit/ hyperactivity disorder. Ann Pharmacother 2004;38:86-90
59. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120
60. Simpson D, Plosker GL. Atomaxetine. A review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004;64:205-222
61. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(Suppl 12):50-55
62. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methyphenidate in light drug users. Drug Alcohol Depend 2002;67:149-156
63. Michelson D, Allen AJ, Busner J, et al. Once-daily Atomaxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1910
64. Popper CW. Antidepressants in the treatment of Attention-deficit/ hyperactivity disorder. J Clin Psyciatry 1997;58(suppl 14):14-29
65. Spencer T, Wilens T, Biederman J, et al. A double-blind crossover comparison ofniethylphenidate and placebo in adults with childhood - onset attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-443
66. Biederman J, Baldessarini RJ, Goldblatt A, Lapey KA, Doyle A, Hesslein PS. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Child Adolesc Psychiatry 1993;32:805-813
67. Popper CW. Combining methylphenudate and clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharm 1995;5:157-166
68. Swanson JM, Flockhart D, Udrea D, et al. Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharm 1995;5:301-304.
69. Conner DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000;39:15-25
70. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit/hyperactivity disorder. Clin Pharmacokinet 2001;40:753-772
71. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiat 1985;24:617-629
72. Hunt RD, Minderaa RB, Cohen DJ. The therapeutic effects of clonidine in attention deficit disorder with hyperactivity: A comparison with placebo and methylphenidate. Psychopharmacol Bull 1986;22:229-236
73. Scahill I, Barloon L, Farkas L. Alpha-2 agonists in the treatment of Attention Deficit Hyperactivity Disorder. JCAPN 1999;12:168-171
74. Fisman S, Steele M. Use of Risperidone in pervasive developmental disorders: A case series. J Child Adolesc Psychopharmacol 1996;6:177-190
75. Simeon JG, Carrey NJ, Wiggeins DM, Milim RP, Hosenbocus SN. Risperidone effects in treatment-resistant adolescents: Preliminary case reports. J Child Adolesc Psychopharm 1995;5:69-80
76. Hardan A, Johnson K, Johnson C, Hrecznyj B. Case study: Treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996;35:1551-1556
77. Ballas CA, Kim D, Baldassano CF, Hoeh N. Modafinil: past, present and future. Expert Rev Neurotherapeutic. 2002;2:449-457
78. Ferraro L, Antoneffi T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABA receptor blockade. Neurepsychopharmacology 1999;20:346-356.
79. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder an open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-235.